Optiscan Imaging (ASX:OIL) revealed its next-generation microscopic medical imaging device InForm specifically designed for pathology workflows, according to a Wednesday filing with the Australian bourse.
The device can be used in a variety of pathology settings, most notably in laboratory medicine, pathology practice, point-of-care, and digital pathology, the filing added.
The new device expands the company into the pathology market, per the filing.
Company shares rose almost 7% in recent Wednesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。